Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.48 |
| ▸ | AOC1 | P19801 | 9/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630670 | 1.00 | LOXL2 (0.52) | LOXL2AOC3AOC1FAAHCD38 | |
| Hydrochloric Acid SCHEMBL30162975 | 0.98 | AOC3 (0.50) | LOXL2AOC3AOC1FAAHCD38 | |
| Hydrochloric Acid SCHEMBL1964470 | 0.98 | AOC3 (0.50) | LOXL2AOC3AOC1FAAHCD38 | |
| SCHEMBL22085299 | 0.85 | LOXL2 (0.48) | LOXL2AOC3AOC1IDO1 | |
| SCHEMBL18986509 | 0.84 | LOXL2 (0.57) | LOXL2AOC3AOC1 | |
| SCHEMBL1272312 | 0.80 | CD38 (0.40) | FAAHCD38GRIN1GRIN2BALDH1A1 | |
| SCHEMBL1272973 | 0.80 | GRIN1 (0.40) | LOXL2FAAHCD38GRIN1GRIN2B | |
| SCHEMBL3088068 | 0.80 | GRIN1 (0.37) | LOXL2FAAHCD38GRIN1GRIN2B | |
| SCHEMBL29525334 | 0.80 | CD38 (0.40) | FAAHCD38GRIN1GRIN2BALDH1A1 | |
| SCHEMBL844759 | 0.80 | GRIN1 (0.37) | LOXL2FAAHCD38GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4683919-A1 | VANIN-1 INHIBITORS | Athos Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250066353-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024196841-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1699761-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066353-A1 | VANIN-1 INHIBITORS | VCAM1, TMBIM6, VNN1 | LOXL2 714/4885AOC3 2620/4885AOC1 1288/4885 |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | LOXL2 3345/4885AOC3 4819/4885AOC1 4701/4885 |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | LOXL2 4451/4885AOC3 4220/4885AOC1 3728/4885 |
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | LOXL2 3480/4885AOC3 2305/4885AOC1 2746/4885 |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | LOXL2 3780/4885AOC3 4335/4885AOC1 4593/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | LOXL2 2527/4885AOC3 2901/4885AOC1 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.